SCHEMBL7579874

SCHEMBL7579874

N#[N+]c1ccc(CC(=O)O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.56
CAMK2A Q9UQM7 1/20 0.56
AKR1B1 P15121 1/20 0.54
LMNA P02545 3/20 0.52
GAA P10253 2/20 0.52
TSHR P16473 2/20 0.52
ABCC4 O15439 1/20 0.52
PTGS1 P23219 1/20 0.52
HTT P42858 1/20 0.52
ALDH1A1 P00352 3/20 0.47
HPGD P15428 3/20 0.47
HSD17B10 Q99714 3/20 0.47
FFAR1 O14842 1/20 0.47
POLB P06746 2/20 0.46
NSD2 O96028 1/20 0.46
GRK2 P25098 1/20 0.46
CASP6 P55212 1/20 0.46
CTDSP1 Q9GZU7 1/20 0.46
KDM4E B2RXH2 2/20 0.45
MAPT P10636 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3246857 0.98 CA2 (0.54) CA2CAMK2AAKR1B1LMNAGAA
SCHEMBL5367742 0.92 LMNA (0.50) CA2CAMK2AAKR1B1LMNAGAA
SCHEMBL3778952 0.92 LMNA (0.50) CA2CAMK2AAKR1B1LMNAGAA
SCHEMBL5367739 0.92 LMNA (0.50) CA2CAMK2AAKR1B1LMNAGAA
SCHEMBL69614 0.81 CA2 (0.79) CA2CAMK2AAKR1B1LMNAGAA
SCHEMBL8144887 0.79 FFAR1 (0.59) CA2LMNAFFAR1P4HTM
SCHEMBL9888582 0.78 CA2 (0.56) CA2CAMK2AAKR1B1LMNAGAA
Hydrochloric Acid SCHEMBL25180348 0.78 CA2 (0.75) CA2CAMK2AAKR1B1LMNAGAA
Hydrochloric Acid SCHEMBL6765874 0.78 CA2 (0.75) CA2CAMK2AAKR1B1LMNAGAA
SCHEMBL13711947 0.78 HDAC8 (0.57) KDM4EHIF1AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119243181-A Method for electrochemically synthesizing rifamycin S from rifamycin SV continuous flow under microscale 河北欣港药业有限公司 2025-01-03 CN claimed
EP-3820629-A1 PROCESS FOR FORMING A POLYMERIC ORGANIC FILM AT THE SURFACE OF A METAL SUBSTRATE USING A GEL Commissariat à l'énergie atomique et aux énergies alternatives (FR) 2021-05-19 EP claimed
EP-3077127-B1 ADHESION PRIMER FOR PAINT COMMISSARIAT ENERGIE ATOMIQUE (FR) 2018-11-14 EP claimed
EP-3077127-A1 ADHESION PRIMER FOR PAINT Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) 2016-10-12 EP claimed
US-20250281681-A1 NEW DEVICES FOR USE FOR TREATING CEREBRAL ANEURYSMS INST NAT SANTE RECH MED (FR) 2025-09-11 US disclosed
EP-4333922-B1 NEW DEVICES FOR USE FOR TREATING CEREBRAL ANEURYSMS INST NAT SANTE RECH MED (FR) 2025-09-03 EP disclosed
CN-119243181-A Method for electrochemically synthesizing rifamycin S from rifamycin SV continuous flow under microscale 河北欣港药业有限公司 2025-01-03 CN disclosed
EP-4333922-A1 NEW DEVICES FOR USE FOR TREATING CEREBRAL ANEURYSMS Institut national de la santé et de la recherche médicale (INSERM) (FR) 2024-03-13 EP disclosed
WO-2022233944-A9 NEW DEVICES FOR USE FOR TREATING CEREBRAL ANEURYSMS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2022-12-15 WO disclosed
WO-2022233944-A1 NEW DEVICES FOR USE FOR TREATING CEREBRAL ANEURYSMS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2022-11-10 WO disclosed
EP-3864191-A1 METHOD FOR TREATING A SPECIFIC METAL PART TO ENHANCE THE CORROSION RESISTANCE THEREOF AND THE ADHESION PROPERTIES THEREOF WITH RESPECT TO A COATING COMPOSITION SUCH AS A PAINT Commissariat à l'énergie atomique et aux énergies alternatives (FR) 2021-08-18 EP disclosed
EP-3820629-A1 PROCESS FOR FORMING A POLYMERIC ORGANIC FILM AT THE SURFACE OF A METAL SUBSTRATE USING A GEL Commissariat à l'énergie atomique et aux énergies alternatives (FR) 2021-05-19 EP disclosed
EP-2676740-B1 Method for the covalent grafting of a polyarylene film on an electrically conductive or semi-conductive surface COMMISSARIAT ENERGIE ATOMIQUE (FR) 2019-06-05 EP disclosed
EP-3077127-B1 ADHESION PRIMER FOR PAINT COMMISSARIAT ENERGIE ATOMIQUE (FR) 2018-11-14 EP disclosed
EP-3077127-A1 ADHESION PRIMER FOR PAINT Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) 2016-10-12 EP disclosed
EP-2676740-A1 Method for the covalent grafting of a polyarylene film on an electrically conductive or semi-conductive surface Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) 2013-12-25 EP disclosed
US-20090232724-A1 METHOD OF SEPARATING METALLIC AND SEMICONDUCTING CARBON NANOTUBES FROM A MIXTURE OF SAME INTERNATIONAL BUSINESS MACHINES CORPORATION 2009-09-17 US disclosed
EP-0970265-B1 METHOD FOR PRODUCING BY ELECTROCHEMICAL PROCESS A CARBON-CONTAINING MATERIAL WITH ITS SURFACE MODIFIED BY ORGANIC GROUPS, USE OF THE MODIFIED MATERIAL CENTRE NAT RECH SCIENT (FR) 2002-07-03 EP disclosed
EP-0970265-A1 METHOD FOR PRODUCING BY ELECTROCHEMICAL PROCESS A CARBON-CONTAINING MATERIAL WITH ITS SURFACE MODIFIED BY ORGANIC GROUPS, USE OF THE MODIFIED MATERIAL CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2000-01-12 EP disclosed
WO-1998044172-A1 METHOD FOR PRODUCING BY ELECTROCHEMICAL PROCESS A CARBON-CONTAINING MATERIAL WITH ITS SURFACE MODIFIED BY ORGANIC GROUPS, USE OF THE MODIFIED MATERIAL CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) (FR) 1998-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090232724-A1 METHOD OF SEPARATING METALLIC AND SEMICONDUCTING CARBON NANOTUBES FROM A MIXTURE OF SAME SOD1, AS3MT, TTN CA2 131/4885CAMK2A 2043/4885AKR1B1 2864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.